» Articles » PMID: 16896704

Large-sized Hepatocellular Carcinoma (HCC): a Neoadjuvant Treatment Protocol with Repetitive Transarterial Chemoembolization (TACE) Before Percutaneous MR-guided Laser-induced Thermotherapy (LITT)

Overview
Journal Eur Radiol
Specialty Radiology
Date 2006 Aug 10
PMID 16896704
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

This study aims to evaluate the efficacy and safety of a neoadjuvant treatment protocol with repeated transarterial chemoembolization (TACE) before MR-guided laser-induced thermotherapy (LITT) for large-sized hepatocellular carcinomas (HCC). Repeated TACE (mean, 3.5 treatments per patient) was performed in 48 patients with neoadjuvant intention (the largest lesion was between 50 and 80 mm in diameter, and there were no more than five lesions). For the TACE treatment, we used 10 mg/m(2) mitomycin, 10 ml/m(2) Lipiodol and microspheres. The tumor volume was measured by MRI. Lipiodol retention of the tumors was evaluated with CT. After the diameter of the tumors had decreased to less than 50 mm, the patients were treated with MR-guided LITT 4 to 6 weeks after embolization. Repeated TACE reduced the tumor size in 32 patients (66.7%), forming the basis for performing MR-guided LITT procedures. These patients received one to four laser treatments (mean, 1.9 per patient) for tumor ablation, resulting in a median survival of 36.0 months after the first treatment. For the remaining patients, no reduction in tumor size was achieved in 12 patients and disease progression in 4 patients. Neoadjuvant TACE appears to be an effective treatment of large-sized HCC, which extends the indication for MR-guided LITT.

Citing Articles

Surgical resection versus thermal ablation: comparison of sequential options after successful TACE downstaging therapy for unresectable hepatocellular carcinoma.

An C, Wu S, Zuo M, Li W, Li K, Wu P Ther Adv Med Oncol. 2025; 17:17588359241306648.

PMID: 39759827 PMC: 11694308. DOI: 10.1177/17588359241306648.


Bench-to-bedside development of multifunctional flexible embolic agents.

Wang D, Rao W Theranostics. 2023; 13(7):2114-2139.

PMID: 37153738 PMC: 10157739. DOI: 10.7150/thno.80213.


Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma.

Mohr I, Vogeler M, Pfeiffenberger J, Sprengel S, Klauss M, Radeleff B J Cancer Res Clin Oncol. 2022; 148(11):3163-3174.

PMID: 35076764 PMC: 9508038. DOI: 10.1007/s00432-021-03900-3.


Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?.

Sparchez Z, Radu P, Bartos A, Nenu I, Craciun R, Mocan T World J Gastrointest Oncol. 2022; 13(12):1896-1918.

PMID: 35070032 PMC: 8713312. DOI: 10.4251/wjgo.v13.i12.1896.


Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status.

Qian K, Zhang F, Allison S, Zheng C, Yang X J Interv Med. 2021; 4(1):1-7.

PMID: 34805939 PMC: 8562266. DOI: 10.1016/j.jimed.2020.10.008.


References
1.
Curley S, Izzo F, Ellis L, Nicolas Vauthey J, Vallone P . Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000; 232(3):381-91. PMC: 1421151. DOI: 10.1097/00000658-200009000-00010. View

2.
Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F . Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002; 224(1):47-54. DOI: 10.1148/radiol.2241011262. View

3.
Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L . Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 1995; 197(1):101-8. DOI: 10.1148/radiology.197.1.7568806. View

4.
Midorikawa T, Kumada K, Kikuchi H, Ishibashi K, Yagi H, Nagasaki H . Microwave coagulation therapy for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2000; 7(3):252-9. DOI: 10.1007/s005340070045. View

5.
Shah S, Riordan S, Karani J, Williams R . Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. QJM. 1999; 91(12):821-8. DOI: 10.1093/qjmed/91.12.821. View